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Commentary
Policy makers struggle with incorporating generalized information into their decision 
making about substance use disorders when they believe their local needs, resources, 
environments and populations differ from other communities. The study by Barbosa et al. is 
a compelling example of the value that simulation modeling can bring to substance use 
policy and resource allocation decisions [1]. In this paper, the authors use a simulation 
model to examine the synergistic effects of providing medications for opioid use disorder 
(MOUD), harm reduction services, and HCV screening and treatment on achieving HCV 
elimination targets among people who inject drugs (PWID) in different areas of the United 
States [2].
The authors model two specific geographic areas that differ in PWID demographics, illicit 
drug use patterns, and availability of MOUD and harm reduction services: a rural county in 
Kentucky and urban San Francisco. Implementing simulation models that are customized to 
different community characteristics can be time-consuming, but is critical to developing 
policy recommendations that are responsive to local conditions and constraints. Even if the 
overall conclusions are robust to differences in community characteristics, as occurred in 
this case where the full scale-up MOUD, harm reduction, and HCV care for PWID was 
preferred in both rural and urban settings, buy-in from decision makers often requires using 
relevant local data whenever possible [3]. The models also show how much additional costs 
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required to implement the full scale up approach over 10 years differ by jurisdiction: $21.6 
million in the rural county versus $872 million in the urban setting. While the lower cost 
might seem more feasible, it may in fact be a greater hurdle for a financially strapped county 
government compared to a municipality such as San Francisco with an annual budget of 
$12.3 billion, including $2.4 billion for public health [4].
These estimated costs do not reflect additional start-up activities that are often required to 
mobilize a community to address barriers to providing services to PWID, including stigma 
and lack of available providers. The HEALing Communities Study recently funded by the 
National Institute on Drug Abuse is seeking to generate evidence about the implementation 
of interventions for preventing and treating opioid use disorder at the local level [5]. Several 
of the authors of this article and one of the authors of this commentary are involved in the 
HEALing Communities Study, which has a substantial economic component that includes 
simulation modeling. The study will be implemented in selected communities in four states 
(Kentucky, Ohio, New York, and Massachusetts) allowing for comparisons among a variety 
of local settings. Because the simulation models will be developed as each community 
selects and rolls out interventions, there will be opportunities to incorporate model results in 
“real time” as resource allocation decisions are being made at the local level, as well as to 
update model inputs with local data as they are collected.
Meaningful engagement between modelers and local decision makers is challenging to 
implement in practice, but represents a compelling ideal to strive for. Feedback from local 
officials helps modelers ensure that their results are relevant to decision making, that they 
balance needs for rigor and timeliness, and that they communicate findings effectively [6]. 
Interaction with policy makers may have the greatest impact in jurisdictions that have 
already made a commitment to improve HCV outcomes. For example, local policy makers 
in New York State and in San Francisco have made commitments towards HCV elimination 
that build on national efforts [7, 8]. The countries of Australia, Georgia and Iceland have 
also established strategies to meet global elimination targets [9, 10].
One way that modelers can assist policy makers is when public entities negotiate with 
pharmaceutical companies to increase the availability of HCV medication. For example, the 
Australian government worked with pharmaceutical companies to negotiate a fixed payment 
over five years in exchange for unlimited volume of HCV medication [11]. The states of 
Louisiana and Washington have recently received Federal approval to negotiate 
supplemental rebate programs for HCV medications for their Medicaid populations [12–15]. 
Both states have negotiated for free medication beyond an expenditure cap in exchange for 
unlimited volume of HCV medication. In order for these “subscription” payment models to 
support HCV elimination goals during the periods covered by the agreements, policy makers 
must forecast local HCV treatment need and design programs that maximize treatment 
uptake. Simulation models can support these efforts. Models that incorporate local 
characteristics, such as those reported by Barbosa et al, represent one step towards 
partnerships between modelers and local policy makers that will drive the efficient use of 
resources to eliminate HCV in PWID.
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